Abstract:Synthesis of new Cu(TBH) and Zn(TBH) complexes were based on hydraone ligand (TBH)–containing thiazine moiety. Structural features and morphology were studied by different spectroscopic tools. Antitumor activity of the prepared compounds was studied. Molecular modeling and molecular docking were studied and correlated with experimental results. QSAR, drug‐likeness, and ADMT were studied. The current study involved production, comprehensive structural analysis, and physicochemical characterizing of two distinctive complexes namely, Cu(TBH) and Zn(TBH); TBH donor ligand: N′‐(1‐(3,6‐dihydro‐4‐hydroxy‐2,6‐dioxo‐2H‐1,3‐thiazin‐5‐yl)ethylidene)‐2‐hydroxybenzohydrazide) using a wide range of analytical methods, including elemental analysis, UV–Vis, FT‐IR, and 1HNMR spectrometry, molar conductivity and magnetic susceptibility measurements, and thermal analysis. According to the findings, chelation can occur through O, N, and O donor atoms of monoanionic chelator for generating mono‐nuclear chelates with tetrahedral geometry for Cu (II) and octahedral geometry for Zn (II). The anticarcinogenic ability of TBH chelator and its coordinated compounds against human liver cancer (HepG‐2) was investigated. The Cu(TBH) complex was found to have selective and promising anticancer activity against a liver cancer cell line, with lower IC50 (liver carcinoma cell line) and higher IC50 (normal human cell line) values than other produced compounds and standard drugs. Utilizing DFT computations, the molecular structures of the TBH and its complexes were verified, offering a detailed understanding of their quantum chemical characteristics. A quantitative structure–activity relationship (QSAR) model, which illustrates the association between DFT‐computed descriptors and biological activities pIC50, was also created using multiple linear regression (MLR) on the synthesized compounds as anticancer medicines. Additionally, there are no issues with the produced compounds' oral bioavailability according to (ROF) Lipinski's rule of five. Furthermore, docking studies of the synthesized TBH chelator and its chelates with CDK2 kinase have been performed to validate the biological findings. According to our findings, the novel Cu(TBH) nanodrug exhibits considerable cytotoxic activity, prompting further study into its pharmacological profile and exploring its potential in drug development.

Synthesis and Anticancer Property of Zn(II) Compounds Nanoparticles Based on Tetrazole Carboxylate Ligands

Two Metal–Organic Coordination Polymers Based on Polypyridyl Ligands: Crystal Structures and Inhibition of Human Spinal Tumour Cells

Bifunctional tetrazole–carboxylate ligand based Zn(II) complexes: synthesis and their excellent potential anticancer properties

Synthesis and anticancer property of two Sm(III) compounds based on tetrazole ligands

Synthesis and anticancer property of three new Cu(II) coordination polymers constructed by the bifunctional substituted-polynitrogen heterocyclic ligands

Novel tetranuclear grid-like Zn(II) complexes derived from dihydrazone pyrimidine derivatives as antitumor agents

Synthesis and Anticancer Property of Three New Ca (II) Compounds Derived from Tetrazole Carboxylate Ligands

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Two Cu(II) coordination polymers based on benzene-1,3,5-tricarboxylate and 1,2,4-triazolide ligands: their crystal structures and application of nanoparticles in anti-esophageal cancer activity evaluation

Synthesis, cytotoxicity and DNA binding of novel Ni(II), Co(II) and Zn(II) complexes bearing pyrimidinyl hydrazone ligand

Dithiocarbazate–Fe III , −Co III , −Ni II , and −Zn II Complexes: Design, Synthesis, Structure, and Anticancer Evaluation

Two Zn(II) coordination polymers: Selective detection Fe3+ ion and inhibitory activity on the liver cancer viability by regulating the prolyl hydroxylase-3

Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

Two Zn( ii ) coordination polymers with anticancer drug norcantharidin as ligands for cancer chemotherapy

A New 3D Zinc (Ii)-Coordination Polymer: Treatment Activity on Lymphoma Combined with Doxorubicin Via Regulating Apoptotic Genes Expression

Synthesis, crystal structures and anticancer studies of Ni (II), Co (III) and Zn (II) complexes based on 5-bromosalicylaldehyde- 2-(2-aminophenyl)benzimidazole Schiff base

Selective Metal‐Coordinated Nanodrugs Based on Thiazine Moiety for Anticancer Therapeutics: Spectroscopic, Theoretical, and Molecular Docking Studies

Dithiocarbazate ligands and their Ni(II) complexes with potential biological activity: Structural, antitumor and molecular docking study

Tris-(2-pyridyl)-pyrazolyl Borate Zinc(II) Complexes: Synthesis, DNA/Protein Binding and In Vitro Cytotoxicity Studies

Anticancer and biological properties of a Zn-2,6-diacetylpyridine bis(thiosemicarbazone) complex